MA45554A - Fusions de binucléase optimisées. - Google Patents
Fusions de binucléase optimisées.Info
- Publication number
- MA45554A MA45554A MA045554A MA45554A MA45554A MA 45554 A MA45554 A MA 45554A MA 045554 A MA045554 A MA 045554A MA 45554 A MA45554 A MA 45554A MA 45554 A MA45554 A MA 45554A
- Authority
- MA
- Morocco
- Prior art keywords
- binuclease
- fusions
- optimized
- optimized binuclease
- binuclease fusions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
- C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/27—Endoribonucleases producing 3'-phosphomonoesters (3.1.27)
- C12Y301/27005—Pancreatic ribonuclease (3.1.27.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662357756P | 2016-07-01 | 2016-07-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA45554A true MA45554A (fr) | 2019-05-08 |
Family
ID=59399475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA045554A MA45554A (fr) | 2016-07-01 | 2017-06-30 | Fusions de binucléase optimisées. |
Country Status (8)
Country | Link |
---|---|
US (2) | US20190241878A1 (fr) |
EP (1) | EP3478830B1 (fr) |
JP (3) | JP7308034B2 (fr) |
CN (1) | CN109790526A (fr) |
AU (1) | AU2017290389A1 (fr) |
CA (1) | CA3029627A1 (fr) |
MA (1) | MA45554A (fr) |
WO (1) | WO2018005954A2 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3202898T (pt) | 2009-11-02 | 2018-12-28 | Univ Washington | Composições de nucleases terapêuticas e métodos |
SG11202001311VA (en) | 2017-08-22 | 2020-03-30 | Sanabio Llc | Soluble interferon receptors and uses thereof |
JP2022516635A (ja) * | 2019-01-04 | 2022-03-01 | リゾルブ セラピューティクス, エルエルシー | ヌクレアーゼ融合タンパク質によるシェーグレン病の処置 |
KR20220152196A (ko) * | 2020-01-11 | 2022-11-15 | 예일 유니버시티 | DNAse1 및/또는 DNAse1L3 결핍에 의해 야기되거나 이와 관련된 질병 또는 장애를 치료, 개선 및/또는 예방하기 위한 조성물 및 방법 |
WO2021252470A2 (fr) * | 2020-06-08 | 2021-12-16 | Yale University | Compositions et méthodes de traitement et/ou de prévention de la coagulopathie et/ou de la septicémie chez des patients souffrant d'infections bactériennes et/ou virales |
CN112322607B (zh) * | 2020-11-20 | 2023-03-28 | 江南大学 | 一种融合型腈水合酶及其应用 |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
EP0088046B1 (fr) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipides en phase aqueuse |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
EP0143949B1 (fr) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Composition pharmaceutique contenant de l'urokinase |
AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
WO1988007089A1 (fr) | 1987-03-18 | 1988-09-22 | Medical Research Council | Anticorps alteres |
US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
US20030108548A1 (en) | 1993-06-01 | 2003-06-12 | Bluestone Jeffrey A. | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
US6348343B2 (en) | 1995-02-24 | 2002-02-19 | Genentech, Inc. | Human DNase I variants |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
US6391607B1 (en) | 1996-06-14 | 2002-05-21 | Genentech, Inc. | Human DNase I hyperactive variants |
ES2300113T3 (es) | 1996-08-02 | 2008-06-01 | Bristol-Myers Squibb Company | Un procedimiento para inhibir toxicidad inducida por inmunoglobulinas que resulta del uso de inmunoglobulinas en terapia y diagnostico in vivo. |
WO1998023289A1 (fr) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | Modulation de la fixation de l'igg au fcrn |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
CA2288600C (fr) | 1997-05-02 | 2010-06-01 | Genentech, Inc. | Procede de preparation d'anticorps multispecifiques presentant des composants heteromultimeres |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
CA2323757C (fr) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Variants d'anticorps et fragments de ceux-ci |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
US20020142374A1 (en) | 1998-08-17 | 2002-10-03 | Michael Gallo | Generation of modified molecules with increased serum half-lives |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
EP1006183A1 (fr) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Récepteurs Fc recombinantes et solubles |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
NZ539776A (en) | 1999-01-15 | 2006-12-22 | Genentech Inc | Polypeptide variants with altered effector function |
ATE440959T1 (de) | 2000-06-28 | 2009-09-15 | Glycofi Inc | Verfahren für die herstellung modifizierter glykoproteine |
GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
EP2354149B1 (fr) | 2000-12-12 | 2017-08-30 | MedImmune, LLC | Molécules à demi-vies longues, compositions et utilisations de celles-ci |
CA2436092A1 (fr) | 2001-01-29 | 2002-08-08 | Idec Pharmaceutical Corporation | Anticorps modifies et procedes d'utilisation |
WO2002096948A2 (fr) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Anticorps tetravalents modifies et procedes d'utilisation |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
EP1487879B1 (fr) | 2002-03-01 | 2012-12-26 | Immunomedics, Inc. | Mutations ponctuelles dans un anticorps bispecifique, permettant d'augmenter le taux de clairance |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
CA2495251C (fr) | 2002-08-14 | 2018-03-06 | Macrogenics, Inc. | Anticorps specifiques du recepteur fc.gamma.riib et procedes d'utilisation de ces anticorps |
ES2562177T3 (es) | 2002-09-27 | 2016-03-02 | Xencor Inc. | Variantes de Fc optimizadas y métodos para su generación |
US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
CA2502904C (fr) | 2002-10-15 | 2013-05-28 | Protein Design Labs, Inc. | Modification d'affinites de liaison pour fcrn ou de demi-vies seriques d'anticorps par mutagenese |
GB2395337B (en) | 2002-11-14 | 2005-12-28 | Gary Michael Wilson | Warning Unit |
AU2004204494B2 (en) | 2003-01-09 | 2011-09-29 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
CA2536408A1 (fr) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Anticorps ameliores possedant une fonction d'effecteur modifiee et procedes de fabrication associes |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
JP2008504002A (ja) | 2003-11-12 | 2008-02-14 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 新生児Fcレセプター(FcRn)結合ポリペプチド改変体、ダイマーFc結合タンパク質、およびそれらに関連する方法 |
US20050249723A1 (en) | 2003-12-22 | 2005-11-10 | Xencor, Inc. | Fc polypeptides with novel Fc ligand binding sites |
JP4762156B2 (ja) | 2004-01-12 | 2011-08-31 | アプライド モレキュラー エボリューション,インコーポレイテッド | Fc領域変異体 |
WO2005092925A2 (fr) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Variantes d'immunoglobuline a l'exterieur de la region fc |
WO2005123780A2 (fr) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Modification des affinites de liaison pour le fcrn ou de la demi-vie serique d'anticorps par mutagenese |
WO2006085967A2 (fr) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | Anticorps monoclonaux optimises anti-cd20 a variants fc |
EP2471813B1 (fr) | 2004-07-15 | 2014-12-31 | Xencor, Inc. | Variantes optimisées de Fc |
WO2006047350A2 (fr) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | Variants d'immunoglobuline igg a fonction effectrice optimisee |
EP1888649A2 (fr) | 2005-05-09 | 2008-02-20 | GlycArt Biotechnology AG | Molecules de liaison a l'antigene possedant des zones fc modifiees et une liaison alteree aux recepteurs fc |
JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー/エス | 二重特異性抗体の生産 |
CN101516388B (zh) | 2006-07-21 | 2012-10-31 | 诺和诺德公司 | 通过o-联糖基化序列的肽的糖基化 |
US8198063B1 (en) | 2006-09-12 | 2012-06-12 | Pro Zyme, Inc | Rapid deglycosylation of glycoproteins |
JP5613876B2 (ja) | 2007-10-15 | 2014-10-29 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 延長された半減期を備えるヒト第ix因子変異体 |
SI2235064T1 (sl) | 2008-01-07 | 2016-04-29 | Amgen Inc. | Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov |
PT3202898T (pt) * | 2009-11-02 | 2018-12-28 | Univ Washington | Composições de nucleases terapêuticas e métodos |
RU2012127383A (ru) | 2009-12-02 | 2014-01-10 | Акселерон Фарма Инк. | Композиции и способы для увеличения времени полужизни fc-слитых белков в сыворотке |
MX352929B (es) | 2010-11-05 | 2017-12-13 | Zymeworks Inc | DISEÑO DE ANTICUERPOS HETERODIMÉRICOS ESTABLES CON MUTACIONES EN EL DOMINIO Fc. |
CA2834626A1 (fr) | 2011-04-29 | 2012-11-01 | University Of Washington | Compositions a base de nuclease therapeutique et procedes associes |
DK2773671T3 (da) | 2011-11-04 | 2021-11-15 | Zymeworks Inc | Udformning af stabilt heterodimert antistof med mutationer i fc-domænet |
US20130336973A1 (en) * | 2012-05-10 | 2013-12-19 | Zymeworks Inc. | Heteromultimer Constructs of Immunoglobulin Heavy Chains with Mutations in the Fc Domain |
WO2013180295A1 (fr) | 2012-06-01 | 2013-12-05 | 日本電信電話株式会社 | Procédé de traitement de transfert de paquets et dispositif de traitement de transfert de paquets |
WO2014004586A1 (fr) * | 2012-06-25 | 2014-01-03 | Zymeworks Inc. | Processus et procédés pour la fabrication efficace d'anticorps asymétriques hautement purs dans des cellules de mammifère |
KR20150036606A (ko) * | 2012-07-13 | 2015-04-07 | 자임워크스 인코포레이티드 | 항-cd3 구조체를 포함하는 이중특이적 비대칭 이형이합체 |
PL3063275T3 (pl) | 2013-10-31 | 2020-03-31 | Resolve Therapeutics, Llc | Terapeutyczne fuzje nukleaza-albumina i sposoby |
US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
WO2016069889A1 (fr) * | 2014-10-31 | 2016-05-06 | Resolve Therapeutics, Llc | Hybrides nucléase-transferrine à visée thérapeutique et procédés associés |
-
2017
- 2017-06-30 JP JP2018569138A patent/JP7308034B2/ja active Active
- 2017-06-30 MA MA045554A patent/MA45554A/fr unknown
- 2017-06-30 WO PCT/US2017/040267 patent/WO2018005954A2/fr unknown
- 2017-06-30 US US16/313,656 patent/US20190241878A1/en not_active Abandoned
- 2017-06-30 EP EP17743419.8A patent/EP3478830B1/fr active Active
- 2017-06-30 CA CA3029627A patent/CA3029627A1/fr active Pending
- 2017-06-30 CN CN201780053637.9A patent/CN109790526A/zh active Pending
- 2017-06-30 AU AU2017290389A patent/AU2017290389A1/en active Pending
-
2021
- 2021-12-23 US US17/560,522 patent/US20220112474A1/en active Pending
-
2022
- 2022-08-01 JP JP2022122570A patent/JP2022153588A/ja active Pending
-
2023
- 2023-12-11 JP JP2023208402A patent/JP2024026334A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220112474A1 (en) | 2022-04-14 |
JP2019530430A (ja) | 2019-10-24 |
US20190241878A1 (en) | 2019-08-08 |
WO2018005954A2 (fr) | 2018-01-04 |
JP7308034B2 (ja) | 2023-07-13 |
AU2017290389A1 (en) | 2019-02-14 |
EP3478830B1 (fr) | 2024-04-10 |
CA3029627A1 (fr) | 2018-01-04 |
EP3478830A2 (fr) | 2019-05-08 |
JP2022153588A (ja) | 2022-10-12 |
JP2024026334A (ja) | 2024-02-28 |
CN109790526A (zh) | 2019-05-21 |
WO2018005954A3 (fr) | 2018-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2018000256A (es) | 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas | |
CL2015002226S1 (es) | Automóvil. | |
CL2015002104S1 (es) | Automovil. | |
CL2015002833S1 (es) | Automovil. | |
CL2014001893S1 (es) | Vehiculo. | |
DK3253762T3 (da) | 9h-pyrrolo-dipyridinderivater. | |
BR112017012364A2 (pt) | pré-tratamento rápido. | |
CL2017000337S1 (es) | Maquina de afeitar. | |
CL2017002511S1 (es) | Contenedor. | |
CL2015002137S1 (es) | Automovil. | |
MA45554A (fr) | Fusions de binucléase optimisées. | |
FR3023988B3 (fr) | . | |
CL2017002510S1 (es) | Contenedor. | |
IT201600084952A1 (it) | Coglifrutta. | |
ES1150114Y (es) | Abarcón. | |
DK3215792T3 (da) | Brænder. | |
IT201600117182A1 (it) | Ribobinatrice. | |
DK3339109T3 (da) | Låseenhed. | |
ES1151158Y (es) | Somier plegable. | |
ITUB20169875A1 (it) | Indumento. | |
IT201700118826A1 (it) | giandujamarcobava.it | |
IT201600132795A1 (it) | Capsulismo. | |
CL2018001670S1 (es) | Automóvil. | |
ES1166583Y (es) | Juego de construcción. | |
CL2018000448S1 (es) | Envase. |